Akebia Therapeutics: Post-Earnings Dip Looks Like A Discounted Entry Ahead Of A Vafseo Inflection

At $3.13 a share, I’m pretty bullish on Akebia (NASDAQ: AKBA ) stock. The 21% sell-off after Q2 earnings looks more like an overreaction than a red flag to me. Sure, the EPS quality wasn’t perfect, but the growthI hold a Master’s degree in Cell Biology and began my career working for several years as a lab technician in a drug discovery clinic, where I gained extensive hands-on experience in cell culture, assay development, and therapeutic research. That scientific foundation gave me an appreciation for the ...